• Petroteq Energy has been developing a proprietary clean surface oil extraction technology that it expects to revolutionize the fuel industry
• Petroteq recently announced that Texas-based energy engineering services company Valkor has contracted Petroteq’s technology for its extraction plants, paying Petroteq associated royalties
• Petroteq expects the licensing of its technology to become a significant part of its business model

Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) is demonstrating the true potential value of the Clean Oil Recovery Technology (CORT) that it has developed for surface tar sands oil extraction in Utah’s rural eastern desert. The company announced July 2 that it has entered into a non-exclusive technology licensing agreement with eastern Texas energy services company Valkor LLC, marking the first in what Petroteq hopes will become a series of licensing agreements for its technology (http://ibn.fm/h70ah).

Since last year, Petroteq has been putting its technology to work at the Utah site it leases, aptly named Asphalt Ridge because of the surface bituminous resource located there. The company has been using its CORT, which is a closed-loop system that extracts fuel oils from the ground and returns the sands “cleaned” to the earth.

Valkor’s agreement to license CORT grants Valkor the non-exclusive right to use Petroteq’s patented technology to engineer, construct, operate and finance oil sands extraction from mining operations to heavy crude at Valkor’s bases of operation.

Petroteq, in return, gains a non-refundable license fee of $2 million per extraction plant and a five percent royalty based on Valkor’s annual gross sales, excluding solvent and water, for so long as the technology is covered by a valid claim in the country in which it is used. Valkor also stipulates that it will invest (or secure investment of) at least $20 million for building a plant by December 2020 and will have in production a minimum of 1,000 barrels per day.

“The licensing model is an important component of the Petroteq business model allowing Petroteq to leverage its proprietary technologies and operating techniques to participate in value created through investment by other companies and strategic investors,” the company’s announcement states.

“In working with Petroteq for the past year at its Asphalt Ridge facility in Utah, it is clear that the Petroteq technology is unique and highly effective. It fits our long-term strategy extremely well,” Valkor CEO Steve Byle noted in the news release.

For more information, visit the company’s website at www.Petroteq.energy

NOTE TO INVESTORS: The latest news and updates relating to PQEFF are available in the company’s newsroom at http://ibn.fm/PQEFF

• Proprietary bioelectronic devices developed by Endonovo Therapeutics target patient pain and inflammation while aiding wound recovery
• SofPulse® safely decreases pain by reducing edema (swelling), which decreases the need for prescription pain medications
• Endonovo’s wearable device can be used to address an array of medical conditions and is FDA-cleared for treating post-operative pain and edema in soft tissue

Endonovo Therapeutics Inc. (OTCQB: ENDV) is transforming the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver Endonovo’s Electroceutical™ Therapy. Targeting inflammatory conditions in vital organs and peripheral tissues, Endonovo’s SofPulse® is clinically proven to significantly speed the recovery process and reduce the need for potentially addictive pain medications, thereby improving the patient’s natural recovery experience (http://ibn.fm/qHmMQ).

The efficacy of SofPulse targeted pulsed electromagnetic field therapy (tPEMF), which uses targeted microcurrents to transmit gentle pulses to the tissue, is well documented and supported by peer-reviewed clinical research. Among the clinical findings for patients using tPEMF are decreases in post-surgery pain, a 2.2-fold reduction in the use of narcotics, vastly improved chronic wound healing and significant reductions in inflammation and edema (http://ibn.fm/2uABB).

Endonovo recently announced a national rollout of its SofPulse post-operative opioid alternative tPEMF therapy device to hospitals, skilled nursing centers, wound care centers and pain management clinics throughout the U.S. According to the company’s news release, Endonovo plans to be in the evaluation stage with 600 hospitals within the next 18 months, employing roughly 300 sales representatives (http://ibn.fm/O9IB8). Endonovo has also entered into an agreement to distribute its SofPulse therapy device to Veterans Administration facilities and Department of Defense health care facilities (http://ibn.fm/R2cGe).

“We believe, based on numerous meetings with doctors and hospital administrators, the level of acceptance of our SofPulse device supports our plans to be in hospitals throughout all 50 states by 2020,” Alan Collier, Endonovo’s chief executive officer, said in the release. “With the public demanding change and options other than opioids, and with very few alternatives to satisfy those demands, SofPulse is a natural and safe replacement to opioids and a solution to this health crisis.”

In 2017, the U.S. Department of Health and Human Services declared a public emergency and announced a five-point strategy to combat the nationwide opioid crisis that includes advancing better practices for pain management (http://ibn.fm/fFBRg). Opioid overdoses accounted for more than 42,000 deaths in 2016, more than any previous year on record, with an estimated 40 percent of opioid overdose deaths involving a prescription opioid.

Endonovo’s Electroceutical Therapy is cleared by the U.S. Federal Drug Administration (FDA) for the palliative treatment of post-surgical pain and edema and is CE-marked in the European Economic Area for the promotion of wound healing and the palliative treatment of post-surgical pain and edema. The Centers for Medicare and Medicaid Services also has national coverage determination for the reimbursement of Electroceutical Therapy for the treatment of chronic wounds.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• Trxade hosts a S2P (supplier to pharmacy) pharmaceuticals trading platform
• Over 10,500 registered pharmacies are listed on Trxade’s platform
• The company achieved record first quarter 2019 financial results driven by an increase in revenues

The proprietors of America’s independent pharmacies may well be cheering as the S2P (supplier to pharmacy) trading platform pioneered by Trxade Group Inc. (OTCQB: TRXD) swings into full gear, for its benefits extend to both trade and customers. The web-based platform not only identifies the best available prices for prescription drugs – a boon to patients – but helps pharmacists avoid negative reimbursement costs, which reduce profit margins. Over 10,500 pharmacies have already registered, and Trxade Group is hoping to convince most, if not all of the 24,000 independent pharmacies that its platform is a better deal when working with traditionally standalone group purchasing organizations (GPO) for secondary sourcing of prescription medication. The message appears to be getting a hearing. The company recently announced record first quarter 2019 financial results driven by an increase in revenues.

In the vast economic sector that is the U.S. pharmaceutical industry – $330+ billion a year – proprietors of independent pharmacies, many of whom are constrained in terms of time and resources, run $3.5 million-per-annum operations while struggling to maintain margins. In the past, they have turned to GPOs and other sourcing programs to reduce the purchase cost of drugs, which the GPOs were supposed to accomplish through the consolidation of buying power. The proof of the pudding, however, is in the eating. Over the past decade, independent pharmacies have been experiencing declining margins due to rising fees and reduced reimbursements from pharmacy benefit managers (PBMs) and volatility in drug costs.

It appears that GPOs have not been able to provide the service needed to these pharmacies. Instead, the PBMs are winning at their expense. Indeed, one study (http://ibn.fm/6lwbh) reported, “Pharmaceutical benefit managers, a once obscure segment of the health care financing landscape, have become industrial behemoths in the U.S. health sector. In 2017, the top PBMs had revenues that exceeded those of the top pharmaceutical manufacturers, for example, Express Scripts reported revenue of $100 billion while Pfizer had revenues of $52 billion.”

Express Scripts is one of three large PBMs, along with CVS Health and OptumRx, that control 78 percent of the market, with 180 million enrollees on their books.

However, the online marketplace hosted by Trxade Group offers pharmacies a real opportunity to reduce purchase costs and much more. The integrated pharmaceutical services company offers not just a web-based purchasing platform for transactions between independent pharmacists and drug distributors (B2B), but also a network of associated pharmacies with its e-hub software; a mail order pharmacy; a warehouse; and drug delivery services. Called the TRxADE Exchange, the platform gives small pharmacies access to the wider pharmaceutical distribution supply chain network, allowing them to search for and view products from manufacturers, buying groups and wholesalers on a real-time and continuous basis.

Other services offered by Trxade Group include RX Guru, an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks. The model aims to ascertain trends and pricing variances that provide significant purchasing opportunities that are not discernible to the rest of the industry.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company’s newsroom at http://ibn.fm/TRXD

• Lexaria developed and out-licenses DehydraTECH to create new (and improve existing) drug-delivery products
• The company is credited with leading the way forward in discovering new ways to effectively deliver CBD into the human body
• Lexaria is helping firms meet supply and demand requirements by creating products that offer lower dosing with higher absorption

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is known for its innovative delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. The company developed drug-delivery platform DehydraTECH and out-licenses the platform to create new (and improve existing) orally ingested products.

DehydraTECH is patented for cannabidiol and all other non-psychoactive cannabinoids, as well as for THC (tetrahydrocannabinol) and psychoactive cannabinoids. Additional patents are expected in 2019 as the company continues to investigate how it’s proprietary edible technology can enhance treatment for Parkinsons, Alzheimers, human hormone delivery, erectile dysfunction and more.

CannabisNewsWire (CNW), a multifaceted financial news and publishing company for private and public entities in the cannabis industry, ran an article titled ‘Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatment’ in which LXRP was featured (http://ibn.fm/8u5ep). CNW credited LXRP for leading the way forward for the cannabis industry in discovering new ways to more effectively deliver CBD into the human body.

The article outlined the ways that the industry has struggled to achieve higher rates of absorption. Current cannabis medicines are poorly absorbed by the body, which consequently increases cost and reduces effectiveness. Companies such as LXRP, however, are working to create better delivery systems that make CBD more accessible and improve more lives.

One of the delivery challenges is the amount of CBD waste created, because the human body can only absorb a small amount of the molecules. DehydraTECH is disrupting this cycle by protecting the product during stomach transit, amplifying intestinal absorption by five to ten times over traditional methods and enabling the drug to bypass first-pass liver metabolism. Third-party lab studies have shown a 15- to 20-minute onset of THC effects in humans when using the edible tech.

Products that use the DehydraTECH drug-delivery platform have been shown to deliver CBD faster than those that use medium-chain triglyceride oils. A recent study reported a 319 percent higher CBD blood concentration at 60 minutes when using the DehydraTECH formulation as opposed to coconut oil (http://ibn.fm/tKbuo). Fatty acids used with DehydraTECH have the added benefit of masking the bitter taste of CBD, allowing a better overall experience for the consumer without the need for added sugars or chemicals.

According to the CNW article (http://ibn.fm/2l3ns), the legal changes in Canada and the United States have made it so that suppliers are unable to meet the increase in demand for CBD. DehydraTECH enables the creation and enhancement of products that use smaller amounts of CBD and remain just as effective, thereby reducing production cost and providing a higher quality experience.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• SGSI is focused on creating and maintaining excellent customer relationships, along with providing proven value, quality, safety and reliability
• The company maintains high standards as it seeks out additional acquisitions
• SGSI is strategically positioned to meet rising demand for 5G, which offers the potential of creating three million jobs, safer cities and stronger economies

Described as a leading single-source provider of end-to-end, next-gen telecommunications networks, Spectrum Global Solutions Inc. (OTCQB: SGSI) services reach across the United States, Canada, Puerto Rico, Guam and the Caribbean. The company’s end-to end offerings include bundled products of full-service engineering, construction, installation, maintenance and professional services. To date, SGSI has completed more than 150,000 projects on wireless, Distributed Antenna System (DAS), wireline and fiber networks.

SGSI is working tirelessly to become the world-class industry leader by which others measure their progress. The company is achieving this by providing the highest value, quality, safety and reliability available on the market, while simultaneously building client relationships that last. To accomplish this, SGSI is investing in the development of a strong team of talented experts and creating strong and consistent shareholder value with continued financial results and growth.

Based out of Longwood, Florida, the company’s subsidiaries make it possible to provide services directly to clientele in 49 states, three U.S. territories and six Canadian provinces. To date, SGSI has:

• engineered over 70,000 sites;
• constructed and installed more than 8,500 towers, antennas, small cells and facilities;
• installed 586,944 strand-miles of fiber;
• re-engaged over 98 percent of clients; and
• maintained a 100 percent accident-free safety record.

SGSI has high standards as it seeks out additional acquisitions. To be considered, candidates must be established and reputable, possess a strong management team, show a history of profitability, be structured for growth, have already established excellent customer relationships and retention and (whether private or public) maintain clean operations with no issues to be passed on through the acquisition.

The company is ready for a 5G-networks rollout this year and is strategically positioned to meet the demand. Over the next five to seven years, according to Deloitte, up to $150 billion in fiber investment will be required in the United States (http://ibn.fm/8V7Kj). Customers are demanding overall better services as they rely more heavily on technology. Coverage, enhanced capacity, private networks and rapid deployment of new apps are in demand. This high demand of excellence and need for 5G positions SGSI in a rapidly growing market as an already-proven provider of cutting-edge services and solutions.

According to Accenture Strategy (http://ibn.fm/LrqBb), the 5G rollout has the potential to create up to three million jobs and drive more than $500 billion in U.S. GDP growth. The rollout will create job growth and economic gains across the United States, as well as making cities and towns safer. Smart city solutions that utilize 5G will be able to manage vehicle traffic and electrical grids, saving billions for local communities and their residents. Cities will also be able to reduce commute times, improve public safety and become more efficient.

As one of the few engineering and installation companies able to provide end-to-end service and bundle products for telecommunications, SGSI is proving itself to be a world-class industry leader.

For more information, visit the company’s website at www.SpectrumGlobalSolutions.com

NOTE TO INVESTORS: The latest news and updates relating to SGSI are available in the company’s newsroom at http://ibn.fm/SGSI

• Legislative changes pertaining to hemp company registration in California are expected to enable widespread cultivation in the state
• Green Hygienics Holdings has already acquired a cultivation license in San Diego County to make full use of the growing California market
• The U.S. hemp industry is forecast to grow rapidly in the years to come; sales are anticipated to more than double in 2020, creating new business opportunities and a number of new jobs across various niches

California is making progress in terms of enabling widespread commercial and industrial hemp cultivation. New industrial hemp regulations in the state establish registration procedures for growers and have already gone into effect (http://ibn.fm/Iys71). As per California law, industrial hemp growers are required to register with their local County Agricultural Commissioner’s Office before initiating cultivation.

The aim of the registration program is to allow the widespread cultivation of hemp across California. Companies like Green Hygienics Holdings Inc. (OTCQB: GRYN) have already established their operations in the lucrative state.

Green Hygienics became registered to cultivate industrial hemp in San Diego County in June 2019. The science-driven, premium cannabis cultivation company announced that it has secured the required permits from the County of San Diego Department of Agriculture, Weights and Measures (http://ibn.fm/xQe7Z).

The company is making effective use of the California Industrial Hemp Farming Act to expand its cultivation capabilities across multiple U.S. states. According to Green Hygienics Vice President of Business Development Matt Dole, California bears considerable opportunities for hemp cultivation firms.

The new state regulations in California come on top of the federal Farm Bill that was passed at the end of 2018. Experts predict that such legislative changes will contribute to the rapid growth of the hemp industry and the creation of numerous new jobs across the U.S.

America’s legal hemp industry generated revenue of $1.1 billion in 2018. The size of the market, however, is anticipated to more than double by 2022 to reach $2.6 billion (http://ibn.fm/6ql3f). Such a massive expansion will result in job creation across multiple fields – from financial services and bookkeeping to marketing and retail.

Global hemp product retail is also positioned for rapid growth. Analysis suggests that global hemp retail sales totaled $3.7 billion in 2018. Sales are anticipated to reach $5.7 billion in 2020 (http://ibn.fm/EEEQI). China is currently the market leader, generating almost $1.2 billion in hemp sales. The U.S. is a close second with $1 billion in sales, and European countries follow with net sales of $980 million. According to analysts, U.S. sales will experience the most rapid jump by 2020. The compound annual growth rate in the period is forecast at 27 percent.

Green Hygienics Holdings is a full-scope premium cannabis cultivation company that targets both the high-end medical and the recreational markets. The company has over 25 years of experience in agricultural science and innovation. Growth plans focus on the development of effective, science-driven cannabis cultivation systems, the creation of premium cannabis products, developing and licensing valuable IP, strategic acquisitions and the launch of global consumer brands.

For more information, visit the company’s website at www.GreenHygienicsHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

• Appointment of Dr. Steven Levin of Johns Hopkins University to Endonovo’s scientific advisory board is expected to help facilitate the introduction of Endonovo’s non-invasive bio-electrical medical devices to hospitals and clinics
• The global wearable medical devices market is expected to grow to nearly $67 billion by 2026 at a CAGR of 26.1 percent
• Endonovo holds 27 patents and numerous trademarks for several proprietary technologies and medical devices

Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of non-invasive electroceutical therapeutic devices, has appointed Dr. Steven Levin, M.D., a national leader in the field of pain management, to its scientific advisory board. Levin is the regional medical director at Johns Hopkins School of Medicine and medical director at Howard County General Hospital in Columbia, Maryland. He is also an assistant professor at Johns Hopkins School of Medicine’s Department of Anesthesiology.

“Dr. Levin’s vast experience with novel therapies in the anesthesiology and pain management field, as well as his strong research interest to improve clinical practice in pain management, will be valuable scientific additions to Endonovo,” Alan Collier, CEO of Endonovo Therapeutics, said in a news release (http://ibn.fm/UFbNO). “As a leader in the field of pain management, Steven will contribute valuable knowledge and expertise as we move our programs forward.”

Levin’s membership in professional and scientific societies has included the American Society of Anesthesiology, the American Pain Society, the American Society of Regional Anesthesia, the Society in Anesthesia and the International Association for the Study of Pain. He is currently the co-chair of the Opioid Stewardship Clinical Community, as well as a clinical design team leader of the Musculoskeletal Center in the Johns Hopkins Health System.

“It is a great opportunity to participate in developing Endonovo’s promising fight to support pain management and healing in a natural and holistic way,” Levin stated in the release. “I look forward to helping guide Endonovo’s breakthrough treatments and fight against the opioid crisis as a member of the scientific advisory board.”

Levin will work with Endonovo to facilitate the introduction of SofPulse to health care facilities and further develop the company’s electroceutical devices pipeline. Endonovo has entered an agreement to distribute SofPulse to Veterans Administration facilities and Department of Defense health care facilities (http://ibn.fm/cc3ew), and the company recently announced its national rollout plan to be in hospitals throughout the nation by 2020 (http://ibn.fm/Us0G7).

SofPulse Electroceutical Therapy is a non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery (http://ibn.fm/V4CbG). SofPulse naturally speeds the healing process, significantly reduces pain and edema (swelling), reduces the need for addictive opioids and narcotics, and improves the patient recovery experience. Cleared by the FDA for treatment of post-surgical pain and swelling in the U.S., SofPulse is also CE-marked in Europe for the promotion of wound health and the palliative treatment of post-surgical pain and edema.

The National Institute on Drug Abuse reports that more than 130 people in the U.S. die each day after overdosing on opioids, while the Centers for Disease Control and Prevention estimates that the opioid crisis costs the nation a cumulative economic burden of more than $78 billion a year (http://ibn.fm/6UcfO).

The global wearable medical devices market is anticipated to grow to $66.8 billion by 2026, a Grandview Research report published in April 2019 suggests (http://ibn.fm/wd5AP). The market is forecast to expand at a CAGR of 26.1 percent over the period, with several factors contributing to the growth. Endonovo’s current portfolio of wearable medical products addresses conditions like liver disease, chronic kidney disease, cardiovascular and peripheral artery disease and ischemic stroke.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• Nabis Holdings has closed on its previously announced initial purchase of a 49 percent interest in Cannova Medical Ltd., with an option to purchase the remaining 51 percent
• The company selected Cannova Medical for its unique approach to consumable cannabis technology and untapped industry potential
• Nabis sees Cannova as a potential disruptor in the edible cannabis industry

Nabis Holdings Inc. (CSE: NAB) (OTC: NABIF) (FRA: 71P), a leading Canadian investment company pursuing specialty investment opportunities in the burgeoning cannabis industry (among others), recently announced that it has now completed the purchase of a 49 percent interest in Cannova Medical Ltd., totaling 2,260,500 shares. Nabis retains the option to acquire the remaining 51 percent interest in Cannova.

Cannova Medical is a provider of innovative solutions for cannabis consumption. Pursuing its interest in investment across all vertically integrated aspects of the cannabis sector, with a focus on strategic revenue generation, Nabis selected Cannova because of its innovative take on consumable cannabis. In connection with this transaction, Nabis will have exclusive distribution rights in North America.

Cannova, based in Israel, is developing an alternative method for cannabis consumption in the form of a sublingual strip. The sublingual strips are infused with cannabis molecules that are produced using a patent-protected process involving the combination of various formulations with water soluble cannabinoids and natural active ingredients. The sublingual strip allows producers to more effectively control dosage quantities and significantly increases the effect of the cannabis, allowing it to be used for a variety of purposes, including pain management, as a concentration aid, as an antidepressant and to support better sleep.

Additionally, Cannova is developing the NovaJet Pro (“NovaJet”), an innovative printing machine that provides producers with the ability to create customized film strips, according to client demand, in real time. The NovaJet is expected to be able to assemble different quantities of cannabinoids and other natural substances, ultimately producing sublingual strips that are highly measured, accurate and tailored to specific demand.

Nabis CEO and Director Shay Shnet sees Cannova as a disruptor in the cannabis space as it relates to the way consumers view consumption (http://ibn.fm/OJlxj). “[Cannova’s] team has developed an innovative solution that largely appeals to consumers looking for convenience compared to current forms of consumption such as smoking, evaporation and ingestion of oil,” he said in a news release. “While we remain focused on our strategic plan for rapid expansion into limited-license states, we also pay close attention to companies that have the potential to disrupt the legal cannabis space. Cannova’s patent-protected solution allows the user to get a customized, personal combination of THC, CBD, and other active ingredients that meet[s] their personal, unique requirements in real time, thus changing the way cannabis is consumed.”

Shnet described Cannova’s product design as one that easily fits into the home of the average consumer, sitting on a countertop with a design akin to an average espresso or coffee machine while utilizing a “next-generation ability to combine various active ingredients.”

Looking to Nabis’s future with Cannova, Shnet spoke highly of the latter’s unique technology and its untapped industry potential. “We’re excited to team up with Nabis to provide cannabis users a safe, accurate and discrete way to consume cannabis,” he continued.

Cannova founder and CEO Omri Schanin indicated a promising future for Cannova with the assistance of Nabis. “The Nabis team, their experience and established network of cannabis-related portfolio, will help boost Cannova to become a cutting-edge leader in the space,” he added.

Utilizing Cannova’s innovative technology, Nabis is looking to disrupt the edibles sector and is well positioned to capitalize on the growing popularity of consumable cannabis.

For more information, visit the company’s website at www.NabisHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to NABIF are available in the company’s newsroom at http://ibn.fm/NABIF

• TRXD sales grew to $1.5 million in Q1 2019; operating income also rose when compared to the same period of the prior year
• The company is adding new independent pharmacies and increasing pharmacy sales
• Mail-order pharmacy services and a newly launched mobile app offer lower prescription drug costs for U.S. consumers

Trxade Group Inc. (OTCQB: TRXD), an integrated pharmaceutical logistical services company that offers a web-based e-hub buying platform for transactions between independent pharmacists and drug manufacturers, reported record Q1 2019 revenues. The company also reported (http://ibn.fm/3NJq6) higher operating income, as it sees “continuing revenue growth and profitability in 2019.”

TRXD reported Q1 2019 sales of $1.5 million, as compared to $852,923 in revenues for the same period of the previous year. Operating income grew in Q1 2019 to $171,759 from $98,728 in Q1 2018. Net income reached $125,229 for Q1 2019, as compared to $82,269 for the same period of the previous year.

“Our 2019 fiscal year is off to a record start and in line with our primary objective of expanding our membership base while simultaneously focusing on increasing their utilization rates,” Trxade Group chairman and CEO Suren Ajjarapu stated in a news release. “At the end of the first quarter, we reported record platform subscribers and transactional revenue along with higher net and operating profits for the same period.”

TRXD’s proprietary trading platform enables independent pharmacies to buy online, directly from national pharmaceutical suppliers. The company attributed its revenue growth to an increase in its fee income from this web-based supplier-to-pharmacy trading platform, as well as increased pharmaceutical sales from its wholly owned subsidiary, Community Specialty Pharmacy LLC.

“Our proprietary software trading platform at www.Trxade.com, which enables independent pharmacies to purchase drugs, is adding new members on a monthly basis and, as a result, enabling us to experience strong top and bottom line growth across the board,” Ajjarapu added. In Q1 2019, TRXD added more than 400 new independent pharmacies, which were successfully onboarded on to the Trxade software trading platform.

On the consumer side, TRXD operates a full-service, mail-order business with pharmacy, warehouse and drug-delivery services, along with a mobile app – www.Delivmeds.com – that enables home delivery. These B2C offerings lower drug costs for U.S. consumers, the company said, and directly challenge the inefficient value chain by providing drug-price transparency and efficient buying and delivery of drugs.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company’s newsroom at http://ibn.fm/TRXD

• Sproutly is a licensed producer with exclusive rights to Infusion Biosciences’ groundbreaking Aqueous Phytorecovery Process (“APP”) technology for naturally water-soluble cannabinoids
• Deloitte estimates that Canada’s cannabis edibles and topicals market could be worth $2.7 billion annually
• The company has entered into an exclusive joint venture with Moosehead Breweries Limited to develop and produce nonalcoholic, cannabis-infused beverages

Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) has reached another milestone by successfully completing the first run of the proprietary Aqueous Phytorecovery Process (“APP”) extraction technology licensed from Infusion Biosciences Inc., Sproutly CEO and Director Keith Dolo announced in a news release (http://ibn.fm/JJ0Yt).

“Sproutly has made significant progress towards building a world-class cannabis beverage and edibles company since going public in July of last year,” Dolo stated in the release. “The successful completion of our first run of the APP extraction technology in Canada marks a major milestone for our company and brings us another step forward in achieving our goal of becoming a leader in the cannabis infused product space.”

The initial APP run took place at Sproutly’s wholly owned Toronto Herbal Remedies Inc., an ACMPR-licensed facility designed and built for cultivating pharmaceutical-grade cannabis for the production and formulation of a natural, truly water-soluble cannabis solution. APP technology extracts water-soluble forms of cannabinoids (Infuz2O) and specific strains of oil-based cannabinoids (Bio Natural Oil), which were both successfully recovered during Sproutly’s first run of the proprietary technology.

“APP technology is a low-cost, gentle method to produce Infuz2O, a groundbreaking discovery that delivers the total effects of the strain of cannabis from which it is made; on-set effects start within approximately 5 minutes and dissipate within approximately 90 minutes,” Dolo stated in an earlier news release (http://ibn.fm/kFEBh).

Sproutly’s premium offering, Infuz2O, is described as “the world’s first and only truly water-soluble cannabis solution” for formulation into beverages. The Infuz2O water-soluble cannabinoids recovered during this first APP run are slated for product formulation and shelf-stability testing for fast-onset cannabis beverages under an exclusive joint venture with OCC Holdings Ltd., an affiliate of Moosehead Breweries Limited (http://ibn.fm/95xol). APP technology is also used in the production of Bio Natural Oils, which deliver the full-spectrum of cannabinoids and terpenes of the strain from which they are made, thus empowering consumers to enjoy the experience of their strains of choice in an edible form (http://ibn.fm/8i8QP).

Deloitte estimates that Canada’s cannabis edibles and beverages sectors will bring $2.7 billion per year into a market that is expected to generate higher profits for retailers (http://ibn.fm/8jRwC). Deloitte’s report, titled ‘Nurturing new growth: Canada gets ready for Cannabis 2.0’, indicates that the new legislation will likely attract consumers who have been reluctant to try traditional cannabis consumption methods.

Sproutly’s team is working diligently, developing and formulating fast-acting and long-lasting Infuz2O and Bio Natural Oil edible products for the Canadian market that meet Health Canada’s specialized regulations. A review of the final regulations for cannabis edibles, extracts and topical products, published on Lexology.com (http://ibn.fm/KLiOb), stated that, while the rules come into force on October 17, 2019, it will likely take until mid-December before consumers find the products on store shelves.

For more information, visit the company’s website at www.Sproutly.ca

NOTE TO INVESTORS: The latest news and updates relating to SRUTF are available in the company’s newsroom at http://ibn.fm/SRUTF